Sign in
Taking people in United StatesNo phase

Interposed Nucleus aDBS for Ataxia

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Recruiting
People taking part
5 people, planned
Started
2 Jun 2026
Expected to end
Jun 2031
Type of study
Interventional
Treatments tested
  • Deep Brain Stimulation
Record updated
20 July 2026

Who can take part

Age
21 years to 89 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • A diagnosis of SCA6 by a movement disorders specialist following established criteria recommended by the Movement Disorders Society
  • A positive genetic test for SCA6
  • A total score ≥ 8 on the Scale of the Assessment and Rating of Ataxia (SARA) rating scale
  • Ability to walk with or without support (score <8 on the 'gait' subsection of the SARA rating scale)
  • Age ≥ 21 years and <89 years
  • Ability to give informed consent for the study
  • Ability to understand the study protocol

Who cannot take part

  • History of previously implanted neurostimulators, pacemakers, defibrillators, or metallic head implants
  • Presence of a concomitant medical condition that, in the investigator's opinion, may interfere with the study participation or gait/balance, for example, severe arthritis
  • Requirement of diathermy, electroconvulsive therapy, or transcranial magnetic stimulation
  • Severe cognitive impairment or dementia, defined as a score <21 on the Montreal Cognitive Assessment (MOCA)
  • Evidence of ataxia due to other etiologies, including but not limited to:; Genetic/inherited disorders other than SCA6; Acquired causes: traumatic brain injury, multiple sclerosis, paraneoplastic cerebellar degeneration, infections or post-infectious cerebellitis, autoimmune ataxias (e.g., anti-GAD, gluten ataxia); Toxic/metabolic causes: alcoholic cerebellar degeneration, vitamin deficiencies; Structural, vascular, or neoplastic causes: cerebellar stroke, tumors, congenital malformations; Suspected multiple system atrophy-cerebellar type (MSA-C)
  • Presence of active and untreated psychiatric illness, severe depression (Beck Depression Inventory ≥ 21), or personality disorder at the discretion of the study team
  • Coagulopathy, uncontrolled epilepsy, or other medical conditions that are considered to place the patient at elevated risk for surgical complications
  • Refractory epilepsy
  • Inability or unwillingness to comply with the study protocol
  • Pregnancy or lactation
  • Active suicidal ideation, defined as fined as a "Yes" response to questions #2-5 within the past one month on the Columbia Suicide Severity Rating Scale, C-SSRS

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 21 and 89 years old?

This trial is currently available in United States.

  • Norman Fixel Institute for Neurological DiseasesGainesville, United StatesContact: Julia C Gonzalez, BATaking people

About the trial

What the trial wants to find out

This is a single-center, open-label study designed to evaluate the feasibility, safety, and preliminary efficacy of cerebellar adaptive deep brain stimulation (aDBS) in adults with spinocerebellar ataxia type 6 (SCA6). A total of 5 participants will be enrolled.

Read full original descriptionShow less

Participants will undergo surgical implantation of deep brain stimulation (DBS) leads targeting the motor interposed nucleus of the cerebellum. The leads will be connected to one or two implantable pulse generators capable of delivering stimulation to deep brain structures and recording neural activity.

Participants will complete up to 18 in-person study visits over a 24-month follow-up period. During these visits, neural signals will be recorded under varying behavioral tasks and stimulation conditions.

Early study visits will be used to identify optimal stimulation parameters and neural biomarkers associated with disease state. These biomarkers will subsequently be used to implement adaptive DBS, in which stimulation amplitude is automatically adjusted in response to recorded neural activity.

Study outcomes will include assessments of safety and feasibility of cerebellar aDBS, as well as preliminary evaluation of its effects on clinical measures.

The group in the trial

  • Adaptive Deep Brain Stimulation (aDBS)Treatment being tested

    Participants will undergo surgical implantation of deep brain stimulation (DBS) leads targeting the motor interposed nucleus of the cerebellum. Approximately one month after implantation, participants will begin conventional DBS (cDBS) programming to identify optimal stimulation parameters, including amplitude, contact configuration, frequency, and pulse width, and to assess stimulation-related adverse effects and device function. Approximately nine months after implantation, stimulation settings will be transitioned to adaptive DBS (aDBS), in which stimulation amplitude is automatically adjusted based on recorded neural activity. Adaptive DBS will be used to evaluate the feasibility, safety, and tolerability of cerebellar aDBS. Clinical outcomes, symptoms, and potential side effects will be assessed throughout the study using participant self-reports, validated clinical rating scales, and wearable devices to collect movement and sleep data.

    Treatment: Deep Brain Stimulation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adaptive Deep Brain Stimulation Targeting the Interposed Nucleus to Treat Spinocerebellar Ataxia
Criteria questions
Built from NCT07325487, who can take part
Record updated
20 July 2026